Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05459168
Other study ID # STUDY00013029
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2021
Est. completion date March 15, 2022

Study information

Verified date May 2022
Source Calm.com, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Using the IDEAS (Integrate, Design, Assess, and Share) framework, the investigators will conduct the following aims: Specific Aim 1: Using two focus groups, the investigators will INTEGRATE formative work, the social cognitive theory, and perspectives from the experienced-user advisory committee (N=20) who will use the current Calm platform to identify design content and features for a standalone cancer-specific app prototype leveraging the commercial infrastructure of the Calm platform. The advisory committee will consist of both cancer patients/survivors (n=10; 5 of each) and health care providers (n=10). Specific Aim 2: DESIGN a meditation app prototype tailored to cancer patients/survivors unique needs including content related to cancer-related experiences, emotions, symptoms, physical and psychological needs, cancer-specific symptom self monitoring, social support and sense of belonging within the app and through Facebook. Specific Aim 3: ASSESS (i.e., beta-test) the prototype's form and function with cancer patients/survivors (N=30). The investigators will use Bowen's feasibility model to determine via surveys and interviews: (a) acceptability (satisfaction, perceived appropriateness, perceived positive/negative effects); (b) demand (use of the app, interest or intention to use); (c) practicality (how it makes them feel, ease of use); (d) adaptation (suggestions for modifications to improve performance for cancer patients/survivors); and (e) integration (how can the app be integrated into the cancer "system") Feasibility benchmarks: >80% of cancer patients/survivors will accept the prototype, demand the prototype for themselves and other cancer patients/survivors, and find it practical. Data from Aim 3 will guide refinement of the prototype to be tested in a fully powered RCT to establish long term engagement (Phase 2). This work will result in an evidence based, cancer-specific meditation app through a commercial platform that can be scaled and sold at discounted costs to clinic providers and directly to patients (SHARE; Phase 3).


Description:

This STTR consists of three aims, each of which are conducted in successive order, with the end result being a cancer-specific meditation app prototype ready for efficacy testing (Phase 2) and direct marketing to the consumer (Phase 3). Aim 1: Using the IDEAS framework, the investigators will INTEGRATE a) perspectives from an informed advisory committee (N=20) about the current Calm platform and b) strategies from the social cognitive theory to design a cancer-specific meditation app prototype. The meaning of the IDEAS stage INTEGRATE is to uncover deeper needs, values, and motivations, engaging key stakeholders (i.e., patients and providers) and use behavioral theory to inspire solutions that are more relevant and acceptable to the target population. Procedures: The advisory committee will consist of informed cancer patients, survivors (n=10; 5 of each) and healthcare providers (n=10; physicians, oncology nurses, cancer care coordinators, directors of integrative programs in cancer centers, and not-for-profit partners; See Support Letters). The advisory committee members are drawn from partnerships with Mays Cancer Center at UT Health San Antonio, MD Anderson, the Mayo Clinic in Scottsdale, AZ and Rochester, NY, University of Arizona, Wake Forest, Leukemia and Lymphoma Society, and the American Cancer Society. Both patients/survivors and providers are included on the advisory committee because providers play a key role in recommending mobile tools to patients to self-manage their symptoms, providers are often uninvolved stakeholders related to app design, and integrating apps into scalable interventions requires support of both patients/survivors and providers. The selection criteria prioritizes the cancer patient and survivor experience, but also includes members who see and hear the preferences, points of reluctance, stated and unstated barriers, and behavioral choices of those they serve in a variety of capacities (medical, ancillary, and direct provision of in-person meditation options). The advisory committee will be asked to: (1) use the Calm app for at least 10 minutes a day for seven days to explore its content and features, (2) keep an informal journal of (a) time of day and time spent using Calm, (b) responses to app options and what motivated them to make certain choices, (c) their experiences during the guided meditations, and (d) ideas about life experiences of a cancer patient to include in prototype, (e) responses to prompts related to strategies from SCT, (e.g., in what ways might the content or features of the app support a sense of social modeling from other cancer patients or providers? How might goal setting and rewards be incorporated appropriately?) and (f) if not a cancer patient or survivor, to reflect upon the perspective of those they treat or serve, and (3) participate in a virtual focus group to provide informed, meaningful and specific input for the prototype. Focus groups have a long history in industry and marketing when the goal is to evaluate responses to products or ideas under development. Considering Coronavirus 2019, virtual focus groups will be conducted based on best-practice guidelines for internet-based qualitative research. One developer from Calm will listen to the focus groups for practical guidance and to meet target needs in the prototype design (Aim 2). The investigators will use Bowen's feasibility framework to explore specific domains of design (acceptability, demand, practicality, adaptation, and integration) (examples are open-ended experiential and cancer-referenced content explorations). The investigators believe this informed-user stage will strengthen the advisory committees' ability to direct the following design and assessment stages where they will be advisors not users. These informed-user focus groups will direct the DESIGN stage in Aim 2, by developing a list of the content and features, prioritized by numbers of mentions and importance emphasized. Milestone for Aim 1: Prioritize a list of 10-12 key content and feature issues to use in designing the prototype and promoting continued engagement. Aim 2: Using the IDEAS framework, the investigators will DESIGN a cancer-specific meditation app prototype. IDEAS framework suggests prototyping leads to objectively stronger final products. The process includes understanding the most frequent requests, deciding on goals and non-goals, and writing out how users should interact with specific features. The investigators will use findings from Aim 1 to rapidly develop server-side Application Programming Interface (APIs) and an app for iOS. Themes and feedback from the feasibility focus groups (e.g., how to cultivate acceptance, demand, practicality, etc.) will be used to extend the current Calm design, APIs, and app so that the content, layout, and features in the app will address specific cancer-related long-term needs. Design: The first step is to mock up user experience, user interface flows, and screens in the mobile app that fit with the values and user requirements from the focus groups. The investigators will mock and create wireframes of potential flow and solutions. The designs will be iterated based on feedback. Once the investigators have clear wireframes and specifications, they will create high-fidelity build mock ups. API and mobile application development: The investigators will build out an interactive prototype by extending Calm's API. The API is a web interface that will help facilitate communication between the mobile application (front-end) and the software running on the server (back-end). It will allow the app to extend its functionalities by making use of other software subroutines running remotely on a server. The APIs will be REST-based and developed in JavaScript using a web framework known as Node.js with a Postgres database. The current Calm system is deployed using Kubernetes, provisioned with Terraform and hosted on Amazon Web Services. All API communication between the servers and clients is done through HTTPS (Hypertext Transfer Protocol Secure) for secure communication. The servers will handle the logic of what, where, when, and how information should be displayed. This will allow the front-end team to move more quickly, focus on user experience, user interface and beautiful animations rather than duplicating the complex business logic. The investigators can move very quickly to automatically change the way content is displayed on the server without user app updates. The API handles authentication, identity management, content, session history, subscriptions, AB test enrollment, assets, surveys and polls, onboarding flows, and scenes. The investigators also have admin endpoints that are deployed inside the virtual private cloud and are not publicly accessible. These routes power the internal tools, which support scene and program uploading, user management, admin activity logs and notes, and debugging. Thus, all aspects of the existing Calm app, from meditation tracks and content to the specific visual and selection paths, even to the inner structural workings of the app can be adapted with recommendations from Aim 1. After specifying the API changes, the investigators will change the API code and front-end app to speak to the API. This results in the prototype app specifically targeting cancer patients and survivors to be used in Aim 3. All data will be encrypted and the patient will use a password to access the app. Security and compliance standards will meet the requirements as a business associate of a healthcare provider, including HIPAA policies and procedures. Aim 3: Using the IDEAS framework, the investigators will ASSESS (i.e., beta-test) the feasibility of the cancer-specific meditation app prototype with a sample of cancer patients/survivors (N=30). The investigators will recruit cancer patients/survivors with varying cancer types and stages, race/ethnicity, rural/urban geographic settings, and genders via social media. The investigators have 100 letters of support from cancer patients/survivors supporting the development of a cancer-specific Calm app. Studies suggest 5-10 participants are sufficient to establish feasibility and detect technical difficulties. The sample size is not to establish efficacy, but the multiple components of feasibility. The investigators have included a larger number to ensure a variety of cancer-related experiences. Beta-test participants will be asked to use the prototype for four weeks (free access) for at least 10 minutes per day, but will be encouraged to use it as much as they would like, mimicking how a new paying member would use the existing Calm app. Participation (meditations completed, time of day, length of time, components used) will be tracked (provided by Calm) over the four weeks. The 4-week period is not to establish efficacy but is an appropriate time to test feasibility. To determine acceptability, demand, and practicality, participants will be asked to complete weekly satisfaction questionnaires in addition to a final overall study satisfaction questionnaire immediately post-intervention using REDCap. Following the 4-week beta-test, and in addition to a satisfaction questionnaire the investigators will ask participants to volunteer for a semi-structured interview to determine, using Bowen's feasibility model, acceptability, demand, practicality, adaptation and integration to optimize potential for uptake, engagement and continued use at recommended levels (i.e., at least 10 min/day). Themes and findings from the interviews will be shared with the advisory committee and used to translate findings into app-relevant recommendations (i.e., further revisions if necessary) for efficacy testing (Phase 2). This approach is similar to methods used in other studies designing and developing mobile apps. Due to COVID-19, the investigators will conduct interviews virtually, based on best-practice guidelines for internet-based qualitative research.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date March 15, 2022
Est. primary completion date February 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Interested cancer patients/survivors (Aim 3) will be asked to complete an eligibility survey via a REDCap survey link. Eligibility criteria is as follows: Patients/survivors will be eligible if they are: - at least 18 years of age - able to read and understand English - identify as a cancer patient (i.e., currently receiving treatment) or a survivor (i.e., prior patient no longer receiving treatment) - willing to download the cancer-specific app prototype to their phone

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Calm Meditation Smartphone App Feedback
Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.
Cancer-Specific Meditation App Prototype Design
Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.
Device:
Cancer-Specific Meditation App Prototype
Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.

Locations

Country Name City State
United States Calm, Inc. San Francisco California

Sponsors (3)

Lead Sponsor Collaborator
Calm.com, Inc. Arizona State University, The University of Texas Health Science Center at San Antonio

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Aim 1: Feasibility: Acceptability as assessed with focus groups Acceptability is defined as satisfaction, intent to continue to use, perceived appropriateness according to Bowen and colleagues feasibility criteria. Questions asked at one week of use of the current Calm platform
Primary Feasibility: Demand as assessed with focus groups Demand is defined as actual use, expressed interest or intention to use, perceived demand according to Bowen and colleagues feasibility criteria. Questions asked at one week of use of the current Calm platform
Primary Aim 1: Feasibility: Practicality as assessed with focus groups Practicality is defined as ability of participants to carry out intervention activities, efficiency/speed/quality of implementation according to Bowen and colleagues feasibility criteria. Questions asked at one week of use of the current Calm platform
Primary Aim 1: Feasibility: Adaptation as assessed with focus groups Adoption is defined as how to promote improvement according to Bowen and colleagues feasibility criteria. Questions asked at one week of use of the current Calm platform
Primary Aim 1: Feasibility: Integration as assessed with focus groups Integration is defined as Integration degree of execution, amount and type of resources needed to implement, factors affecting ease of implementation according to Bowen and colleagues feasibility criteria. Questions asked at one week of use of the current Calm platform
Primary Aim 3: Feasibility: Acceptability as assessed with survey Acceptability is defined as satisfaction, intent to continue to use, perceived appropriateness according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 1
Primary Aim 3: Feasibility: Acceptability as assessed with survey Acceptability is defined as satisfaction, intent to continue to use, perceived appropriateness according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 2
Primary Aim 3: Feasibility: Acceptability as assessed with survey Acceptability is defined as satisfaction, intent to continue to use, perceived appropriateness according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 3
Primary Aim 3: Feasibility: Acceptability as assessed with survey Acceptability is defined as satisfaction, intent to continue to use, perceived appropriateness according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 4
Primary Aim 3: Feasibility: Acceptability as assessed with survey Acceptability is defined as satisfaction, intent to continue to use, perceived appropriateness according to Bowen and colleagues feasibility criteria. Questions will be asked with a post-intervention (week 4) satisfaction survey
Primary Aim 3: Feasibility: Acceptability as assessed with interview Acceptability is defined as satisfaction, intent to continue to use, perceived appropriateness according to Bowen and colleagues feasibility criteria. Questions will be asked with a post-intervention (week 4) structured interview
Primary Aim 3: Feasibility: Demand as assessed with survey Demand is defined as actual use, expressed interest or intention to use, perceived demand according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 1
Primary Aim 3: Feasibility: Demand as assessed with survey Demand is defined as actual use, expressed interest or intention to use, perceived demand according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 2
Primary Aim 3: Feasibility: Demand as assessed with survey Demand is defined as actual use, expressed interest or intention to use, perceived demand according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 3
Primary Aim 3: Feasibility: Demand as assessed with survey Demand is defined as actual use, expressed interest or intention to use, perceived demand according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 4
Primary Aim 3: Feasibility: Demand as assessed with survey Demand is defined as actual use, expressed interest or intention to use, perceived demand according to Bowen and colleagues feasibility criteria. Questions will be asked with a post-intervention (week 4) survey
Primary Aim 3: Feasibility: Demand as assessed with interview Demand is defined as actual use, expressed interest or intention to use, perceived demand according to Bowen and colleagues feasibility criteria. Questions will be asked with a post-intervention (week 4) structured interview
Primary Aim 3: Feasibility: Demand captured via Calm-provided data Calm will track weekly minutes of meditation participation for each participant. Calm-provided data capturing meditation participation at post-intervention (week 4)
Primary Aim 3: Feasibility: Practicality as assessed with survey Practicality is defined as ability of participants to carry out intervention activities, efficiency/speed/quality of implementation according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 1
Primary Aim 3: Feasibility: Practicality as assessed with survey Practicality is defined as ability of participants to carry out intervention activities, efficiency/speed/quality of implementation according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 2
Primary Aim 3: Feasibility: Practicality as assessed with survey Practicality is defined as ability of participants to carry out intervention activities, efficiency/speed/quality of implementation according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 3
Primary Aim 3: Feasibility: Practicality as assessed with survey Practicality is defined as ability of participants to carry out intervention activities, efficiency/speed/quality of implementation according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 4
Primary Aim 3: Feasibility: Practicality as assessed with survey Practicality is defined as ability of participants to carry out intervention activities, efficiency/speed/quality of implementation according to Bowen and colleagues feasibility criteria. Questions will be asked with a post-intervention (week 4) survey
Primary Aim 3: Feasibility: Practicality as assessed with interview Practicality is defined as ability of participants to carry out intervention activities, efficiency/speed/quality of implementation according to Bowen and colleagues feasibility criteria. Questions will be asked with a post-intervention (week 4) structured interview
Primary Aim 3: Feasibility: Adaptation as assessed with survey Adoption is defined as how to promote improvement according to Bowen and colleagues feasibility criteria. Questions will be asked with a weekly satisfaction survey (week 1 to week 4)
Primary Aim 3: Feasibility: Adaptation as assessed with survey Adoption is defined as how to promote improvement according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 1
Primary Aim 3: Feasibility: Adaptation as assessed with survey Adoption is defined as how to promote improvement according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 2
Primary Aim 3: Feasibility: Adaptation as assessed with survey Adoption is defined as how to promote improvement according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 3
Primary Aim 3: Feasibility: Adaptation as assessed with survey Adoption is defined as how to promote improvement according to Bowen and colleagues feasibility criteria. Questions will be asked with a satisfaction survey after week 4
Primary Aim 3: Feasibility: Adaptation as assessed with interview Adoption is defined as how to promote improvement according to Bowen and colleagues feasibility criteria. Questions will be asked with a post-intervention (week 4) structured interview
Primary Aim 3: Feasibility: Integration as assessed with survey Integration is defined as Integration degree of execution, amount and type of resources needed to implement, factors affecting ease of implementation according to Bowen and colleagues feasibility criteria. Questions will be asked with a post-intervention (week 4) survey
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients